Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
– Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million – – GAAP Diluted EPS […]
Corporate
Subscribe to our newsletter
We won’t send you spam
Tik4invest provide accurate and up-to-date information, however, we can not always guarantee its accuracy or completeness. The content on this website is for information use only and should be taken as professional financial advice. It is important to do your own research and consult with a professional financial advisor before making any financial decision. We are not responsible for any actions you take based on the information on this website.
Learn
Help
- Affiliate Disclaimer
- Affiliate Partners
- Disclaimer
- Privacy Policy
- Terms of Use
-
Contact Us
800-577-1915 - info@tik4invest.com